Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice: Role of endothelin

Journal of Clinical Investigation

Volumn 101, Issue 12, 1998, Pages 2780-2789

  Chatziantoniou, Christos ^a,c   Boffa, Jean Jacques ^a   Ardaillou, Raymond ^a   Dussaule, Jean Claude ^b  

^a HÔPITAL TENON   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

Author keywords

Extracellular matrix; Hypertension; Nephroangiosclerosis; Renal fibrosis

Indexed keywords

BOSENTAN; COLLAGEN TYPE 1; ENDOTHELIN; ENDOTHELIN RECEPTOR; LUCIFERASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE ACTIVATION; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MALE; MOUSE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRANSGENIC MOUSE;

EID: 0032526251     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2132     Document Type: Article

References (41)

1. Weistucch, J.M., and L.D. Dworkin. 1992. Does essential hypertension cause end-stage renal disease? Kidney Int. 41:S33-S37.
2. Yoshioka, K., M. Tohda, T. Takemura, N. Akano, K. Matsubara, A. Ooshima, and S. Maki. 1990. Distribution of the type I collagen in human kidney diseases in comparison with type III collagen. J. Pathol. 162:141-148.
3. Palmer, R.M., D.S. Ashton, and S. Moncada 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 333:664-666.
4. Yanisigawa, M., H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi, Y. Mitsui, Y. Yazaki, K. Goto, and T. Masaki. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:411-415.
5. Hayakawa, H., and L. Raij. 1997. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension (Dallas). 29:235-241.
6. Garg, U.C., and A. Hassid. 1989. Nitric-oxide generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83:1774-1777.
7. Hirata, Y., Y. Takagi, Y. Fukuda, and F. Marumo. 1989. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 78:225-228.
8. Chua, B.H.L., C.J. Krebs, C.C. Chua, and C.A. Diglio. 1992. Endothelin stimulates protein synthesis in smooth muscle cells. Am. J. Physiol. 262(Endocrine Physiol. 31):E412-E416.
9. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J. Clin. Invest. 83:708-712.
10. Li, J.S., R. Larivière, and E.L. Schiffrin. 1994. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy? Hypertension (Dallas). 24:183-188.
11. A-receptor antagonist. Circulation. 96:1593-1597.
12. Bouriquet, N., M. Dupont, A. Herizi, A. Mimran, and D. Casellas. 1996. Preglomerular sudanophilia in L-NAME hypertensive rats: involvement of endothelin. Hypertension (Dallas). 27:382-391.
13. Baylis, C., B. Mitruka, and A. Deng. 1992. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90:278-281.
14. Ribeiro, M.O., E. Antunes, G. De Nucci, S.M. Lovisolo, and R. Zatz. 1992. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension (Dallas). 20:298-303.
15. Arnal, J.F., L. Warin, and J.B. Michel. 1992. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J. Clin. Invest. 90:647-652.
16. Bou-Gharios, G., L.A. Garrett, J. Rossert, K. Niederreither, H. Eberspaecher, C. Smith, C. Black, and B. de Crombrugghe. 1996. A potent far-upstream enhancer in the mouse proα2(I) collagen gene results expression of reporter genes in transgenic mice. J. Cell Biol. 134:1333-1344.
17. Chatziantoniou, C., and W.J. Arendshorst. 1993. Angiotensin receptor sites in renal vasculature of rats developing genetic hypertension. Am. J. Physiol. 265(Renal Fluid Electrolyte Physiol. 34):F853-F862.
18. Chatziantoniou, C., M.D. Pauti, F. Pinet, D. Promeneur, J.C. Dussaule, and R. Ardaillou. 1996. Renin release is impaired after nitric oxide inhibition. Kidney Int. 49:626-633.
19. Clozel, M., V. Breu, G.A. Gray, B. Kalina, B.M. Löffler, K. Burri, J.M. Cassal, G. Hirth, M. Müller, W. Neidhart, and H. Ramuz. 1994. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:228-235.
20. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:248-251.
21. Benigni, A., N. Perico, F. Gaspari, C. Zoja, L. Belizzi, M. Cabanelli, and G. Remuzzi. 1991. Increased renal endothelin in rats with reduced renal mass. Am. J. Physiol. 260(Renal Fluid Electrolyte Physiol. 29):F331-F339.
22. Rossert, J., and B. de Crombrugghe. 1996. Type I collagen: structure, synthesis, and regulation. In Principles of Bone Biology, Academic Press, San Diego, CA. 127-142.
23. Striker, L., P.D. Killen, E. Chi, and G.E. Striker. 1984. The composition of glomerulosclerosis. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab. Invest. 51:181-192.
24. Li, J.S., and E.L. Schiffrin. 1995. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension (Dallas). 25:495-500.
25. Arnal, J.F., J.B. Michel, and D.G. Harrison. 1995. Nitric oxide in the pathogenesis of hypertension. Curr. Opin. Nephrol. Hypertens. 4:182-188.
26. Raij, L., and C. Baylis. 1995. Editorial review: glomerular actions of nitric oxide. Kidney Int. 48:20-32.
27. Xu, Y., J.F. Arnal, N. Hinglais, M.D. Appay, I. Laboulandine, J. Bariety, and J.B. Michel. 1995. Renal hypertensive angiopathy. Comparison between chronic NO suppression and DOCA-salt intoxication. Am. J. Hypertens. 8:167-176.
28. Trachtman, H., S. Futterweit, and P.C. Singhal. 1995. Nitric oxide modulates the synthesis of extracellular matrix proteins in cultured rat mesangial cells. Biochem. Biophys. Res. Commun. 207:120-125.
29. Garg, U.C., and A. Hassid. 1989. Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am. J. Physiol. 257(Renal Fluid Electrolyte Physiol. 26):F60-F66.
30. Craven, P., R.K. Studer, J. Felder, S. Phillips, and F.R. Derubertis. 1997. Nitric oxide inhibition of transforming growth factor-β and collagen synthesis in mesangial cells. Diabetes. 46:671-681.
31. Ketteler, M., W. Border, and N. Noble. 1994. Cytokines and L-arginine in renal injury and repair. Am. J. Physiol. 267:F197-F207.
32. Moreau, P., H. Takase, C.F. Küng, S. Shaw, and T.F. Lüscher. 1997. Blood pressure and vascular effects of endothelin blockage in chronic nitric oxide deficient hypertension. Hypertension. 29:763-769.
33. Pollock, D., and J. Polakowski. 1997. ET-A receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat. J. Am. Soc. Nephrol. 8:1054-1060.
34. Rivzi, M., and P.R. Myers. 1997. Nitric oxide modulates basal and endothelin induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J. Mol. Cell Cardiol. 29:1779-1789.
35. Phelan, M., S. Perrine, M. Brauer, and D.G. Faller. 1995. Sickle erythrocytes, after sickling, regulate the endothelin-1 gene and protein in human endothelial cells in culture. J. Clin. Invest. 96:1445-1451.
36. Boulanger, C., and T. Lüscher. 1990. Release of endothelin from the porcine aorta. J. Clin. Invest. 85:587-590.
37. Thompson, A.C., R. Valeri, and W. Lieberthal. 1995. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am. J. Physiol. 269(Heart Circulatory Physiol. 38):H743-H748.
38. Benigni, A., C. Zoja, D. Corna, S. Orisio, L. Longaretti, T. Bertani, and G. Remuzzi. 1993. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 44:440-444.
39. Benigni, A., C. Zoja, D. Corna, S. Orisio, D. Facchinetti, T. Bertani, and G. Remuzzi. 1996. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am. J. Kidney Dis. 27:416-423.
40. Nakamura, T., I. Ebihara, H. Tomino, and H. Koide. 1995. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int. 47:481-489.
41. Hocher, B., C. Thöne-Reineke, P. Rohmeiss, F. Schmager, T. Slowinski, V. Burst, F. Siegmund, T. Quertermous, H.H. Neumayer, W.D. Schleuning, and F. Theuring. 1997. Endothelin-1 transgenic mice develops glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J. Clin. Invest. 99: 1380-1389.